var data={"title":"Necitumumab: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Necitumumab: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/791592?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=necitumumab-patient-drug-information\" class=\"drug drug_patient\">see &quot;Necitumumab: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45695272\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Cardiopulmonary arrest:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Cardiopulmonary arrest and/or sudden death occurred in 3% of patients treated with necitumumab in combination with gemcitabine and cisplatin. Closely monitor serum electrolytes, including serum magnesium, potassium, and calcium, with aggressive replacement when warranted during and after necitumumab administration.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Hypomagnesemia:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Hypomagnesemia occurred in 83% of patients receiving necitumumab in combination with gemcitabine and cisplatin, and was severe in 20% of patients. Monitor patients for hypomagnesemia, hypocalcemia, and hypokalemia prior to each dose of necitumumab during treatment and for at least 8 weeks following completion of necitumumab. Withhold necitumumab for Grade 3 or 4 electrolyte abnormalities. Replete electrolytes as medically appropriate.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45820933\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Portrazza</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45695280\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antineoplastic Agent, Epidermal Growth Factor Receptor (EGFR) Inhibitor;</li>\n      <li>\n        Antineoplastic Agent, Monoclonal Antibody</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45746067\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> For patients with a prior grade 1 or 2 infusion reaction, premedicate (prior to all subsequent necitumumab infusions) with diphenhydramine (or equivalent). For patients with a recurrent grade 1 or 2 infusion reaction, premedicate (prior to all subsequent necitumumab infusions) with diphenhydramine (or equivalent), acetaminophen, and dexamethasone (or equivalent).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Non-small cell lung cancer (squamous), metastatic:</b> IV: 800 mg on days 1 and 8 of each 3-week treatment cycle (in combination with gemcitabine and cisplatin); continue until disease progression or unacceptable toxicity (Thatcher 2015).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">In the study, gemcitabine and cisplatin were administered for a maximum of 6 cycles, while patients without disease progression continued necitumumab as single agent therapy (Thatcher 2015).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45746068\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:-2em;margin-left:2em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45746069\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling; however, based on pharmacokinetics, dosage adjustment is not likely necessary. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45746070\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mild to moderate impairment: There are no dosage adjustments provided in the manufacturer&rsquo;s labeling; however, based on pharmacokinetics, dosage adjustment is not likely necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Severe impairment: There is no dosage adjustment provided in the manufacturer&rsquo;s labeling (has not been studied).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45746071\" class=\"block dot drugH1Div\"><span class=\"drugH1\">Dosing: Adjustment for Toxicity</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dermatologic toxicity:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Grade 3 rash or acneiform rash: Withhold treatment until symptoms resolve to grade 2 or lower, then resume necitumumab with the dose reduced to 400 mg for at least 1 treatment cycle. If symptoms do not worsen, may increase the dose to 600 mg and then 800 mg in subsequent cycles.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Grade 3 rash or acneiform rash that does not resolve to grade 2 or lower within 6 weeks: Permanently discontinue.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Grade 3 rash or acneiform rash that worsens or is intolerable at the 400 mg dose: Permanently discontinue.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Grade 3 skin induration/fibrosis: Permanently discontinue.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Grade 4 dermatologic toxicity: Permanently discontinue.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Electrolyte abnormality:</b> Grade 3 or 4 electrolyte abnormality: Withhold treatment; may resume when electrolyte abnormality has improved to grade 2 or lower (replete electrolytes as appropriate).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Infusion-related reactions:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Grade 1: Reduce infusion rate by 50%.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Grade 2: Interrupt infusion until signs/symptoms have resolved to grade 1 or 0, then resume with the rate reduced by 50% for all subsequent infusions. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Grade 3 or 4: Permanently discontinue.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Thromboembolic events:</b> Serious or life-threatening VTE or ATE: Discontinue treatment.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45820934\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Portrazza: 800 mg/50 mL (50 mL) [contains polysorbate 80]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45820932\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46781100\" class=\"block dosfc drugH1Div\"><span class=\"drugH1\">Dosage Forms Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Portrazza is produced in genetically engineered mammalian NS0 cells.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45746073\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV: Infuse over 60 minutes using an infusion pump. Infuse through a separate line. Flush with sodium chloride 0.9% at the end of infusion. Do not infuse with other medications or with electrolytes. Monitor for infusion reactions; reduce infusion rate by 50% for grade 1 infusion reaction; interrupt infusion for grade 2 infusion reaction.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Necitumumab should be administered prior to gemcitabine and cisplatin (Thatcher 2015).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45695268\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Non-small cell lung cancer (squamous), metastatic:</b> First-line treatment of metastatic squamous non-small cell lung cancer (NSCLC) in combination with gemcitabine and cisplatin</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Limitations of use: Not indicated for treatment of non-squamous non-small cell lung cancer.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45741443\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Necitumumab may be confused with bevacizumab, nivolumab, pembrolizumab, ramucirumab.</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Portrazza may be confused with Arzerra.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45760200\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse reaction percentages reported as part of a combination regimen with gemcitabine and cisplatin.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Headache (11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Skin toxicity (79%; grades 3/4: 8%), skin rash (44%; grades 3/4: 4%), acneiform eruption (15%; grades 3/4: 1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Hypomagnesemia (43% to 83%; grades 3/4: 20%), hypocalcemia (45%; grades 3/4: 6%; with albumin corrected: 36%; grades 3/4: 4%), hypophosphatemia (31%; grades 3/4: 8%), hypokalemia (28%; grades 3/4: 5%), weight loss (13%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Vomiting (29%), diarrhea (16%), stomatitis (11%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Venous thromboembolism (9%; grades 3/4: 5%), arterial thromboembolism (5%; grades 3/4: 4%), pulmonary embolism (5%), cardiorespiratory arrest (3%), deep vein thrombosis (2%), cerebrovascular accident (&le;2%), ischemia (&le;2%), myocardial infarction (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Acne vulgaris (9%), paronychia (7%), pruritus (7%), xeroderma (7%), skin fissure (5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Immunologic: Antibody development (4%; neutralizing: 1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ophthalmic: Conjunctivitis (7%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Hemoptysis (10%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Infusion related reaction (2%; grade 3: &lt;1%)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45695274\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">There are no contraindications listed in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45741447\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; <b>Cardiopulmonary arrest: [US Boxed Warning]: Cardiopulmonary arrest and/or sudden death occurred in a small percentage of patients treated with necitumumab in combination with gemcitabine and cisplatin. Monitor serum electrolytes closely, including serum magnesium, potassium, and calcium, with aggressive replacement when warranted during and after necitumumab administration.</b> Continue electrolyte monitoring for at least 8 weeks after the last dose. Some cardiopulmonary events were fatal; many of those patients had comorbid conditions (including a history of coronary artery disease, hypomagnesemia, COPD, and/or hypertension). Patients with significant coronary artery disease, MI within 6 months, uncontrolled hypertension or uncontrolled heart failure were excluded from the squamous cell non-small cell lung cancer study.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Dermatologic toxicity: Dermatologic toxicity, including rash, dermatitis anceiform, acne, dry skin, pruritus, generalized rash, skin fissures, maculo-papular rash, and/or erythema occurs commonly; may be severe. Skin toxicity usually developed within the first 2 weeks of treatment and resolved within 17 weeks after onset. May require treatment interruption, dose reduction, or discontinuation. Patients should minimize exposure to the sun.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; <b>Hypomagnesemia: [US Boxed Warning]: Hypomagnesemia occurred in a majority of patients receiving necitumumab in combination with gemcitabine and cisplatin; hypomagnesemia was severe in one-fifth of patients. Monitor for hypomagnesemia, hypocalcemia, and hypokalemia prior to each dose of necitumumab during treatment and for at least 8 weeks following completion of necitumumab. Withhold necitumumab for Grade 3 or 4 electrolyte abnormalities. Replete electrolytes as appropriate.</b> May resume treatment when hypomagnesemia and related electrolyte abnormalities are improved to grade 2 or lower. The median time to development of hypomagnesemia was 6 weeks after treatment initiation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Infusion reactions: Infusion-related reactions have been reported with necitumumab, usually after the first or second infusion. Premedication was not routinely administered prior to the first dose in the squamous cell NSCLC study. Monitor for signs/symptoms of infusion reaction. Discontinue for serious or life-threatening reactions.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Thromboembolism: Venous and arterial thromboembolic events (VTE and ATE) were observed with necitumumab, including grades 3 and 4 events and some fatalities. The most common VTEs were deep vein thrombosis and pulmonary embolism and the most common ATEs were cerebral stroke and ischemia and MI. Discontinue necitumumab for serious or life-threatening VTE or ATE. The incidence of VTE may be higher in patients &ge;70 years of age (compared to patients under age 70).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Non-squamous NSCLC: Necitumumab is not indicated for use in patients with non-squamous NSCLC. In a study of necitumumab in combination with pemetrexed and cisplatin for the treatment of metastatic non-squamous NSCLC, patients experienced increased serious and fatal toxicities and cardiopulmonary arrest/sudden death within 30 days of the last dose of necitumumab (compared to pemetrexed and cisplatin without necitumumab).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45733088\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45733085\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=105609&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:0em;display:inline\">There are no known significant interactions.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45741445\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Necitumumab is expected to cross the placenta. Based on animal data and the mechanism of action, necitumumab is expected to cause fetal harm if administered during pregnancy. Women of reproductive potential should use effective contraception during therapy and for 3 months after the last dose.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45741446\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if necitumumab is excreted into breast milk; however, human IgG antibodies can be detected in breast milk. Due to the potential for serious adverse reactions in the nursing infant, breast-feeding is not recommended by the manufacturer during therapy or for 3 months after the last dose.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45746076\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Serum electrolytes, including magnesium, potassium, and calcium (prior to each dose during treatment and for at least 8 weeks following completion). Signs/symptoms of infusion-related reactions, dermatologic toxicity, and thromboembolism.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45744652\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Necitumumab is a recombinant human IgG1 EGFR monoclonal antibody which binds (with a high affinity) to the ligand binding site of the EGFR receptor to prevent receptor activation and downstream signaling (Thatcher 2015).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45744654\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: V<sub>dss</sub>: 7 L</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: ~14 days</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46105222\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Portrazza Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">800 mg/50 mL (50 mL): $5,093.81</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49940063\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Portrazza (AT, CZ, DE, DK, EE, GB, HR, LV, NO, PL, SK);</li>\n      <li>Porttrazza (LT);</li>\n      <li>Protrazza (PT)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Portrazza (necitumumab) [prescribing information]. Indianapolis, IN: Eli Lilly and Company; November 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Thatcher N, Hirsch FR, Luft AV, et al; SQUIRE Investigators. Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial. <i>Lancet Oncol</i>. 2015;16(7):763-774.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/necitumumab-drug-information/abstract-text/26045340/pubmed\" target=\"_blank\" id=\"26045340\">26045340</a>]</span><span class=\"doi\">10.1016/S1470-2045(15)00021-2</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 105609 Version 35.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F45695272\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F45820933\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F45695280\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F45746067\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F45746068\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F45746069\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F45746070\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adjustment for Toxicity\" href=\"#F45746071\" class=\"outlineLink\">Dosing: Adjustment for Toxicity</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F45820934\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F45820932\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms Considerations\" href=\"#F46781100\" class=\"outlineLink\">Dosage Forms Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F45746073\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F45695268\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F45741443\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F45760200\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F45695274\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F45741447\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F45733088\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F45733085\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F45741445\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F45741446\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F45746076\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F45744652\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F45744654\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F46105222\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F49940063\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/105609|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=necitumumab-patient-drug-information\" class=\"drug drug_patient\">Necitumumab: Patient drug information</a></li></ul></div></div>","javascript":null}